Neurodegenerative Diseases: current treatment algorithm and potential investment opportunities covered in a lates research report

This report examines the entire neurodegenerative disease therapy area, with a particular focus on the three most prevalent neurodegenerative disorders: Alzheimer’s disease (AD), Parkinson’s disease (PD) and multiple sclerosis (MS).

Pune, India - March 14, 2018 /MarketersMedia/ —

AD and PD represent the most pressing challenges within the disease cluster, due to rapidly increasing prevalence driven by aging populations. Both AD and PD remain ineffectively treated despite substantial investment into R&D by pharmaceutical companies, due to high clinical trial failure rates. As a result there are no disease-modifying therapies for these two indications, with available treatments able to provide only marginal symptomatic relief. MS, the autoimmune disease of the CNS, contrasts with the rest of this cluster, as it affects a different population demographic, and has a lucrative pharmacological market following breakthrough success in the past decade.
Access Report Details at: https://www.themarketreports.com/report/frontier-pharma-neurodegenerative-diseases-protein-misfolding-targets-and-neuromodulators-dominate-the-first-in-class-pipeline-and-lead-the-way-as-potential-disease-modifying-therapies-in-ad-and-pd
Reasons To Buy
• Appreciate the current clinical and commercial landscapes by considering disease symptoms, pathogenesis, etiology, co-morbidities and complications, epidemiology, diagnosis, prognosis and treatment options.
• Identify leading products and key unmet needs within the market.
• Recognize innovative pipeline trends by analyzing therapies by stage of development, molecule type and molecular target.
• Assess the therapeutic potential of first-in-class targets. Using proprietary matrix assessments, first-in-class targets in the pipeline have been assessed and ranked according to clinical potential. Individual matrix assessments are provided for targets categorized into four major classes: protein misfolding, neuromodulators, immunomodulators and neuroprotectants. The most promising first-in-class targets are reviewed in greater detail.
• Consider first-in-class pipeline products with no prior involvement in licensing and co-development deals, which may represent potential investment opportunities.
Get this report at: https://www.themarketreports.com/report/buy-now/935553
Scope
• Unmet need is extremely high in AD and PD, with MS showing continued promise in the development of effective therapies
• What are the most important etiological risk factors and pathophysiological processes implicated in AD, PD and MS?
• What is the current treatment algorithm?
• How effective are current therapies for these indications, and how does this impact prognosis?
• The AD pipeline is large and contains a very high proportion of first-in-class product innovation.
• Which molecule types and molecular targets are most prominent across AD, PD and MS?
• What are the connections, in terms of first-in-class innovation, between AD, PD and MS?
• Which first-in-class targets are most promising?
Inquire for more details at: https://www.themarketreports.com/report/ask-your-query/935553

Contact Info:
Name: Shirish Gupta
Email: sales@themarketreports.com
Organization: The Market Reports
Address: SF-29, Sacred World, Wanawadi
Phone: 16314071315

Source URL: https://marketersmedia.com/neurodegenerative-diseases-current-treatment-algorithm-and-potential-investment-opportunities-covered-in-a-lates-research-report/314330

For more information, please visit https://www.themarketreports.com/report/frontier-pharma-neurodegenerative-diseases-protein-misfolding-targets-and-neuromodulators-dominate-the-first-in-class-pipeline-and-lead-the-way-as-potential-disease-modifying-therapies-in-ad-and-pd%20

Source: MarketersMedia

Release ID: 314330

More News From Daily Xtreme

The Latest: Kvitova back at 1st Grand Slam final since 2014

Jan 24, 2019

MELBOURNE, Australia — The Latest at the Australian Open on Thursday (all times local): 3:45 p.m. Petra Kvitova has beaten Danielle Collins 7-6 (2), 6-0 to return to a Grand Slam final for the first time since winning the Wimbledon title in 2014. It's also the first in what she has called her "second career" following her return from injuries sustained in a home invasion in the Czech Republic in late 2016. The 28-year-old Kvitova will play for the Australian Open title against either U.S. Open champion Naomi Osaka or Karolina Pliskova. Kvitova missed the Australian Open in 2017 while...

Vogue editor joins push to re-name Margaret Court Arena

Jan 24, 2019

MELBOURNE, Australia — Vogue editor Anna Wintour has added her voice to those calling for the renaming of Margaret Court Arena at the Australian Open because of the tennis great's outspoken condemnation of same-sex marriage. Wintour is an avid tennis fan who has been at Melbourne Park this week and spent time in the stadium player boxes of Serena Williams and Roger Federer She used a speech at an Australian Open function on Thursday to raise the issue. "I find that it is inconsistent with the sport for Margaret Court's name to be on a stadium that does so much...

Peers, Kontinen 1st into men's doubles final in Australia

Jan 24, 2019

MELBOURNE, Australia — John Peers and Henri Kontinen have combined to become the first pair through to the men's doubles final after beating Leonardo Mayer and Joao Sousa 6-1, 7-6 (6) at the Australian Open. Peers and Kontinen, who combined to win the 2017 Australian Open doubles title, will play either the American team of Ryan Harrison and Sam Querrey or the French combination of Pierre-Hugues Herbert and Nicolas Mahut. The women's singles finalists will be determined later Thursday. Two-time Wimbledon winner Petra Kvitova was playing Danielle Collins in the first of the semifinals on Rod Laver Arena, followed by...

50 years past last men's Slam, Laver says it'll happen again

Jan 24, 2019

MELBOURNE, Australia — Fifty years after Rod Laver won the last true Grand Slam in men's tennis, he is fairly confident the feat will be replicated one day, unlikely as it may seem. "It's got to happen again," the Australian left-hander said Wednesday at the Australian Open. While Steffi Graf won all four major tennis tournaments in one season in 1988, no man has done it other than Don Budge in 1938 and Laver in 1962 and 1969. Serena Williams and Novak Djokovic each managed to collect four major trophies in a row but spread out over two seasons. Laver's...

Column: Don't write off Serena or Federer just yet

Jan 24, 2019

MELBOURNE, Australia — Tempting as it might be, don't write off Serena Williams or Roger Federer just yet. Sure, both are 37, and they're showing their age. Yes, both are gone from the Australian Open, each with a loss to a far-younger opponent. Williams exited Wednesday in the quarterfinals against 26-year-old Karolina Pliskova of the Czech Republic after wasting four match points and a 5-1 lead in the third set; Federer went out Sunday in the fourth round against 20-year-old Stefanos Tsitsipas of Greece. And, well, there also are these facts to consider: — Federer failed to make it to...

NHL Livescore